Nektar Therapeutics (NKTR) Total Non-Current Liabilities (2010 - 2026)

Nektar Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $178.6 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 24.24% year-over-year to $178.6 million; the TTM figure through Mar 2026 stood at $178.6 million (down 24.24% YoY), while the FY2025 annual figure was $181.9 million, down 22.86% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $178.6 million, down from $181.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $416.2 million in Q1 2022, with the low at $178.6 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $262.4 million (2023), against an average of $277.2 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities decreased 9.01% in 2022, then declined 27.17% in 2023.
• Nektar Therapeutics' Total Non-Current Liabilities stood at $336.4 million in 2022, then decreased by 22.0% to $262.4 million in 2023, then retreated by 10.11% to $235.9 million in 2024, then fell by 22.86% to $181.9 million in 2025, then declined by 1.84% to $178.6 million in 2026.
• Business Quant data shows NKTR's Total Non-Current Liabilities at $178.6 million in Q1 2026, $181.9 million in Q4 2025, and $211.2 million in Q3 2025.